| New from NCI |
| TMIST Breast Screening Trial |
 |
|
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography: standard digital mammography (2-D) and a newer technology called tomosynthesis mammography (3-D). |
| Breast Changes and Conditions |
 |
|
This page can help you learn about symptoms during your lifetime that are not cancer, as well as follow-up tests used to diagnose breast conditions and treatments for specific breast conditions. |
HIV Infection and Cancer Risk
This fact sheet has been completely revised and includes cancers that pose an increased risk to people infected with HIV, risk estimates, and updated references. |
Timing and Sequence Are Critical for Combination Immunotherapy
In a study in mice, two immune checkpoint inhibitors given at the same time did not stop breast cancer growth. The combination was more effective and safer if the two inhibitors were given in a specific sequence. |
New Approval for Acute Myeloid Leukemia
FDA has approved gemtuzumab ozogamicin (Mylotarg™) for some patients with acute myeloid leukemia (AML) that expresses a protein called CD33.
|
| PDQ Summary Updates |
Laryngeal Cancer Treatment
Our PDQ summary on laryngeal cancer has updated information on treatment options and the treatments that are used for the different stages of the cancer. |
Male Breast Cancer Treatment
We’ve revised our PDQ summary on male breast cancer with updated information about risk factors and the treatment of metastatic disease.
|
| Drug Information Updates |
New Drug for Leukemia
We’ve added a drug summary for daunorubicin and cytarabine liposome. It was recently approved by FDA to treat certain types of acute myeloid leukemia. |
New Drug for Lymphoma
We’ve added a new drug summary for copanlisib hydrochloride. It was recently approved by FDA to treat follicular lymphoma, which is a type of non-Hodgkin lymphoma. |
Nivolumab to Treat Liver Cancer
We’ve updated our drug information summary on nivolumab to include the recent FDA approval for the treatment of hepatocellular carcinoma, which is a type of liver cancer. |
Pembrolizumab for Gastric (Stomach) Cancer
Our drug summary on pembrolizumab now includes treatment of cancer of the stomach and gastroesophageal junction. It was approved by FDA to treat certain patients whose disease got worse with other treatment. |
